Highly Profitable, OTC Private Label, Health Home Testing Diagnostic Kits Company 

American HealthCare Capital is proud to be the exclusive representative of a well-established OTC Drug private labeling development, manufacturing, and sales Company for sale. Founded in 2009, the company operates in three Health, Beauty, and Home Product operating segments. These include Cough Drops, Antacids, Durable Medical Equipment, Drugs of Abuse Tests, Family Planning products, Skincare and sunscreens, Sanitary Pads, and Paper Goods.

The company is establishing a NEWCO spinoff company for its Home Testing Private-Label Kits. These will include six products: an Early Detection Pregnancy test, a Digital Pregnancy Rapid Test, an Ovulation Kit, a Drugs of Abuse Test for both 1 Drug Oral Test Kit and 6 Drug Oral Test Kits, and a COVID-19 & FLU A+B Home Multi Test.

Financial Overview

The Company will utilize its 15 years of expertise in Private Labeling to establish a separate Home Testing company. The Company will use its strong existing customer base of distributors and 25,000 retail stores to sell its six Private-Label Home Testing products and transfer its existing business. Historic revenues in Home Testing Kits in 2023 and 2024 were $984,035 and $836,043, respectively.

The Company has a robust customer base. They have secured new contracts with existing customers to expand diagnostic Home Testing products. Its top three customers, CVS, 7-Eleven, and Army/Air Exchange, have executed purchase orders of about $2.5 million for Home Testing Kits. These will go live in May, June, and August of this year. This will increase the 2025 revenues by approximately $1.5 million in 2025. The 2025 plan is for revenues of about $2.0 million and EBITDA of $840,000 or an EBITDA margin of 41%.

The Company is expected to receive FDA approval for its newest Private-Label product, COVID-19 & FLU A+B Home Multi Test, during the fourth quarter of 2025. In the interim, the company uses another 3rd party vendor’s product at lower margins to secure the initial customer contracts. When the company’s new FDA-approved product goes live, it will significantly increase gross profit and could generate $20 million in revenues over the next few years. The 2026 forecast is expected to generate annual net revenue of $11.0 million with an EBITDA of $5.0 million (45%).

Key investment highlights include:

Self-Testing Market growing at 8.4% CAGR to 2030

Global market size in 2024 of $11 billion

Private label expertise with Branding, Manufacturing, Logistics, and Distribution

Strong Retail presence – 25,000 stores and distribution channels

Self-Testing Kits in 3 sectors of Family Planning, Drug of Abuse, and Covid-19 & Flu A+B

2025 product sales to existing customers with $2.5 million in new Contracts/Purchase Orders.

Pipeline – FDA approval of Covid-19 & FLU A+B Home Multi Test expected in Q4 2025

Significant sales driver for $20 million and margin enhancement

Seller is committed to growth and product expansion with 25% to 30% equity rollover

Deal Structure and Asking Price

The transaction involves selling 70 to 75 percent ownership in NEWCO at a $6 million valuation, plus an earnout for the Founder’s ongoing involvement and incentive for further growth. The Founders will keep a minority stake and continue to work with the new partner for long-term growth. It excludes cash, accounts receivable, and working capital, which will not be transferred into the new company. The Founders seek a strategic partner to add value and resources to grow the Company to the next level.

$1 Million+ EBITDA, Fast Growing, Highly Profitable Healthcare Staffing and Outsourcing Company   

American Healthcare Capital is proud to be the exclusive representative of a high-growth, U.S. based, offshore healthcare staffing and outsourcing company for sale. Founded in 2022, the company specializes in providing HIPAA-compliant virtual staffing and administrative services to U.S. healthcare organizations, including medical billing, coding, scheduling, and EMR integration. The company is well-positioned to offer certified virtual nursing resources very soon.

Financial Overview

The business has scaled rapidly, reaching $1.3 million in revenue in 2024 with a projected $2.1 million for 2025. Profit margins have exceeded 47%, supported by a 63-person offshore team and zero in-office overhead. The company operates with a lean infrastructure, having grown exclusively through client referrals and without sales or marketing costs.

The seller is the sole founder and operator and seeks a strategic or capital partner to purchase a majority interest (60–75%) at a $6 million valuation., with a rollover of minority equity. The founder is open to remaining in an operational or advisory role and has a strong management layer already in place, ensuring business continuity post-transaction.

This company serves a growing demand in the U.S. healthcare system—helping providers combat labor shortages, rising costs, and administrative inefficiencies. It is ideally positioned for buyers focused on platform growth in revenue cycle management, healthcare BPO, healthcare staffing or private equity roll-up strategies.

Key investment highlights include:

Scalable offshore infrastructure

No dependency on government payors (100% cash clients)

High gross and EBITDA margins

Strong retention and organic growth

Sector with 10% CAGR growth to 2030

Deal Structure and Asking Price

The transaction involves selling 60 to 75 percent ownership in the company at a $6 million valuation plus an earnout. The Founder will keep a minority stake and collaborate with the new partner for long-term growth. The asking price excludes cash, accounts receivable, and working capital, which will be retained by the seller. An earn-out is highly desirable above the current valuation to provide buyer flexibility and align with the Founder’s ongoing involvement and incentive for further growth.

This is a strategic opportunity to acquire a high-margin, recession-resilient business that addresses one of the most urgent challenges in healthcare today: operational efficiency. For serious inquiries only. NDA and seller approval are required before circulating the Confidential Information Memorandum (CIM).

$1.25 Million EBITDA | Fast Growing & High-Margin Hospitalist Group | | Asset-Light & Scalable Across U.S.

American Healthcare Capital is proud to be the exclusive representative of an established, physician-led hospitalist organization operating in Central Florida that is seeking strategic or capital partners to support its next phase of growth. Founded in 2017, the group provides 24/7 inpatient care across multiple acute care hospitals, skilled nursing facilities (SNFs), rehabilitation centers, and long-term acute care (LTAC) hospitals. The clinical team is composed of board-certified/board-eligible physicians and advanced practice providers who manage patients from admission through discharge with a strong focus on reducing readmissions and improving hospital throughput.

The company offers full-spectrum inpatient care, including medical management of surgical patients, discharge coordination with referring physicians, and round-the-clock coverage. This enables hospital partners to achieve greater operational efficiency, clinical consistency, and improved patient outcomes.

The business operates under established contracts with multiple healthcare facilities and boasts a lean cost structure with no capital expenditures required—no office leases, tenant improvements, or equipment investments—allowing for rapid scaling and high margin sustainability.

Financial Performance

2023202420252026REVENUE$1,732,660$1,945,632$2,617,700$3,000,000EBITDA$544,757.93$765,836$1,064,000$1,250,000MARGIN %33.1139.2340.64%41.6%

The company has demonstrated consistent year-over-year growth with robust EBITDA margins above 40%, driven by its efficient, low-overhead operations. The platform is well-positioned for further expansion and offers significant value for potential partners seeking exposure to the hospitalist sector.

Key Investment Highlights

Recurring Facility Contracts: Long-term, active service agreements with hospital systems and post-acute facilities.

High EBITDA Margins: Demonstrates strong financial performance with operational scalability.

No Capex Requirements: Clean and simple business model, ready to scale without major investment in physical infrastructure.

Growth-Ready Team: A dedicated group of providers already in place, with capacity to grow the clinical footprint.

Strategic Expansion Paths:Geographic growth through contracts with additional facilities.Provider recruitment to increase coverage and reduce burnout.Telemedicine integration to extend coverage into rural or underserved areas.Entry into value-based care models (ACOs, Medicare Advantage).

Diversification into post-discharge and outpatient care.

Management

There are a total of 4 physicians, including the lead doctor and CEO, as well as additional 6 team members consisting of Advanced Registered Nurse Practitioners, Physician Assistants and a Clinical Manager that supports the operation. All team members and physicians are expected to remain post-acquisition.

Reason for Sale

The founder is seeking a strategic or financial partner to help scale the business and capitalize on emerging growth opportunities. The seller is open to a majority equity sale while retaining rolled equity and remaining active in operations, offering a unique opportunity for a partner to benefit from continued growth with a committed operator.

Valuation Guidance and Asking Price

Based on the company’s high margin of profitability, scalability, light-asset requirements, and low operational risk, this business opportunity asking price is $10 million including an earn out. The asking price excludes cash, accounts receivables, and working capital. The seller will retain up to 20% Equity.

$3 Million Revenue Dental Staffing Company

American Healthcare Capital is please to exclusively introduce a unique turnkey dental staffing company for sale. The company has proven itself to be incredibly robust, having thrived through the various economic downturns and COVID.

The company has longstanding relationships and contracts with the most notable dental businesses, schools, government and non-profit players. They are perfectly positioned for expansion horizontally and vertically, beyond its current coverage area with minimal to no investment.

Financial Overview

The company’s revenue has had a steady increase over the years. Revenue in 2021 was $1,350,573 and grew to $1,941,841 in 2022. In 2023, revenue was $2,587,730 with EBITDA of $602,541. Revenue for 2024 was $ 2,444,748 with EBITDA of $721,441. Revenue for 2025 was $3,087,074 with EBITDA of $800,000.

Staff Overview

The owner is looking to retire but is willing to assist during a transitional period. The rest of the staff is expected to stay on under new ownership.

Asking Price

The asking price for this opportunity is $5.6 Million.

$2.5 Million Revenue, Highly Profitable & Scalable Digital Dental Laboratory Opportunity Seeking Co-Investors

American HealthCare Capital is pleased to exclusively present a digital dental laboratory opportunity. The Company was established in the mid-2000s as a digital scanning laboratory primarily focused on modern dentistry technology related to the rising popularity of dental implants as a tooth replacement option. What started as a tech-driven project has evolved into a thriving enterprise, offering a comprehensive suite of digital products, advanced treatment planning solutions, and a wealth of educational resources curated by dentists for dentists.

In 2020, a group of visionary investors recognized the potential in the company’s vision and joined their venture. Together, they’ve been on an incredible journey of growth and innovation, driven by a shared passion for transforming the dental industry. The company’s commitment to progress led them to explore the world of AI software for treatment planning, expanding their offerings to include full arch surgical guides, particularly for cases involving toothless patients. Beyond products, they have launched a training academy, approved by the American Academy of General Dentistry-Pace, serving as both an educational hub and a valuable resource for dentists seeking to stay ahead in the ever-evolving technological landscape.

The Company’s commitment to progress led them to explore the world of AI software for treatment planning, expanding their offerings to include full arch surgical guides, particularly for cases involving toothless patients. Beyond products, they have launched a training academy, approved by the American Academy of General Dentistry-Pace, serving as both an educational hub and a valuable resource for dentists seeking to stay ahead in the ever-evolving technological landscape.

Financial Overview

The Company’s business model is based on custom orders prescribed by licensed dentists and a subscription model with recurring revenues. Since 2019, and despite COVID pandemic, the Company revenues have been steady, ranging between $3 million and $4 million with an EBITDA margin of approximately 20%. Between 2019-2025. The revenue declined in 2024 and 2025 due to the general headwind for dental industry over the increased interest rates, but EBITDA remained about the same. The company expects to generate $2.5 million in revenue and $550,000 EBITDA in 2026.

Asking Price

The present owners/investors, who have played a major role of this business are extending an invitation for collaboration. Whether it’s through a joint-venture model or a majority stake acquisition, they’re seeking the right partner to amplify the current success and explore new horizons together. The asking price is $4 million. The Seller’s are open to all types of deal structures, including retained and roll-over equity and also an earn-out. The asking price excludes, cash, inventory, accounts receivables, working capital and any real estate.

Center Based Pediatric ABA Therapy Company in New Jersey

American HealthCare Capital is pleased to exclusively introduce a pediatric ABA therapy company for sale in New Jersey. The company provides center-based ABA Therapy services, rooted in naturalistic, play-based programming and supported by a purpose built, Artificial Intelligence enabled technology stack to drive outsized scale. Since its inception, the company has grown into a market-leading provider with strong payer relationships, robust clinical outcomes, and a proven framework for de novo expansion.

Payer Mix and Patient Demographic

The company’s payer mix is 90% MCO/Medicaid and 10% commercial insurance. The company is credentialed with most major carriers, such as Aetna, Horizon BCBS, Cigna, Humana, United Healthcare, NJ Family Care, Magellan, Optum, and Magellan. They only serve pediatric patients.

Financial Overview

The company has developed and implemented a proven market penetration strategy, supported by attractive de novo unit economics, that will continue to drive growth in both existing and new states. Their de novo experience has allowed them to develop a “model center” with consistent metrics and a predictable growth trajectory.

The company has developed and implemented a proven market penetration strategy, supported by attractive de novo unit economics, that will continue to drive growth in both existing and new states. Their de novo experience has allowed them to develop a “model center” with consistent metrics and a predictable growth trajectory.

They have enjoyed explosive growth, reaching nearly $1.4 million in 2024. They continue to grow their census at an intentionally steady pace, and they grossed over $1.73 million with an adjusted EBITDA of $408,921. The goal is to ramp up to 32 clients (max capacity) in 2026, at which point their run rate will be $3 million with an adjusted EBITDA of $500,000.

Through 2025, the company was focused solely on full time clients, or those with at least 35 – 40 hours per week. In 2026, they will start taking on part-time clients, which is expected to conservatively boost annual revenue by $600,000 – $800,000, based on the existing local demand and waitlist.

Staff Overview and Exit Plan

The staff consists of a full spectrum of clinical leadership, certified clinicians and highly-trained administrative support, all of whom are expected to stay on under new ownership. Current ownership is not involved in the day-to-day operations and is focused on other endeavors. They would consider maintaining an advisory role with the company.

Asking Price

The sellers are seeking a buyer who sees the value in the infrastructure they have built and desires to continue scaling the business. They are seeking a price of $1.5 million and are open to a deal that includes rollover equity and an earn out, as they are confident and invested in the company’s ongoing success.